AstraZeneca gets CDSCO nod to import and market critical anti-bleeding drug in India

Andexanet Alfa is a novel and life-saving antidote designed to reverse the effects of anticoagulant medications in emergency situations.

January 24, 2024 12:09 am | Updated January 29, 2024 04:51 pm IST - Bengaluru

City-based AstraZeneca Pharma India Ltd., biopharmaceutical firm, on Tuesday said it has received approval from Central Drugs Standard Control Organisation (CDSCO) for importing and marketing of Andexanet Alfa in India.

Andexanet Alfa is a novel and life-saving antidote designed to reverse the effects of anticoagulant medications in emergency situations. It is well-tolerated and facilitates the early restart of anticoagulation following a bleeding event. The therapy is administered through an intravenous (IV) bolus over a duration of 15-30 minutes, followed by a 2-hour infusion, as per a company statement.

This ground-breaking treatment would address life-threatening or refractory bleeding associated with the use of Factor Xa (FXa) inhibitors, it further said.

Sanjeev Panchal, country president and MD, AstraZeneca India, said: “With this approval, we are working to make this important medicine available for patients on FXa inhibitors who have life-threatening or uncontrolled bleeding.”

With the increasing critical role of FXa inhibitors in managing thrombotic events and atrial fibrillation-related stroke risks, the approval of Andexanet Alfa represented a significant milestone, addressing a crucial need in the medical industry, said Anil Kukreja, Vice-President, Medical Affairs and Regulatory, AstraZeneca India.

“Major bleeding occurs in approximately 4-6% of patients treated with oral FXa inhibitors, and Andexanet Alfa stands as the sole reversal agent authorized for individuals undergoing treatment with apixaban or rivaroxaban facing life-threatening or refractory bleeding,” he added.

This CDSCO approval underscored AstraZeneca’s commitment to advancing medical solutions that addressed critical healthcare needs, ensuring that healthcare providers in India have access to innovative treatments that can make a meaningful difference in patient outcomes, claimed the pharma company.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in


Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.